Abstract
Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013.
Highlights
We describe coxsackievirus A16 encephalitis in a patient who was receiving treatment with the monoclonal antibody (MAb) obinutuzumab
Sequencing of the virion protein 1 gene obtained directly from RNA extracted from Cerebrospinal fluid (CSF) identified the virus as coxsackievirus A16 [3]
Obinutuzumab has been approved by the US Food and Drug Administration for treatment of chronic lymphocytic leukemia
Summary
Feldmann); and University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali Crimean–Congo hemorrhagic fever virus: new outbreaks, new discoveries. A fatal case of Crimean– Congo haemorrhagic fever in Mauritania: virological and serological evidence suggesting epidemic transmission. Trans R Soc Trop Med Hyg. 1990;84:573–6.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
